Kommoss, Felix K. F.
Stichel, Damian
Schrimpf, Daniel
Kriegsmann, Mark
Tessier-Cloutier, Basile
Talhouk, Aline
McAlpine, Jessica N.
Chang, Kenneth T. E.
Sturm, Dominik
Pfister, Stefan M.
Romero-Pérez, Laura
Kirchner, Thomas
Grünewald, Thomas G. P.
Buslei, Rolf
Sinn, Hans-Peter
Mechtersheimer, Gunhild
Schirmacher, Peter
Schmidt, Dietmar
Lehr, Hans-Anton
Sahm, Felix
Huntsman, David G.
Gilks, C. Blake
Kommoss, Friedrich
von Deimling, Andreas
Koelsche, Christian http://orcid.org/0000-0001-8763-8864
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (70112499, 70112257)
Dr. Leopold and Carmen Ellinger Stiftung
Article History
Received: 7 November 2019
Accepted: 19 November 2019
First Online: 25 November 2019
Compliance with ethical standards
:
: PS: grants from MSD, BMS, Roche, Astra Zeneca, Novartis, Sanofi-Aventis, Chugai, Illumina and Thermo Fisher; personal fees from MSD, BMS, Roche, Astra Zeneca, AbbVie, Ipsen and Novartis. FS: lecturing honoraria from Illumina, Medac and Agilent; board member of AbbVie. SMP and AvD: patent pending for a “DNA-methylation based method for classifying tumors”. AvD: issued patent for IDH1R132H and BRAFv600E antibodies. All other authors declare no conflict of interest.
: This study was performed in accordance with the ethical standards of the institutional research committee and the Declaration of Helsinki.